Zepatier is a once-daily, fixed-dose combination of Merck & Co’s second-generation protease inhibitor, grazoprevir, and the company’s NS5A inhibitor, elbasvir. The combination is currently approved in the US and EU for the treatment of genotype 1/4 (GT-1/4) chronic hepatitis C virus patients. Within Japan, Zepatier is approved for the treatment of GT-1 patients only.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Zepatier : Hepatitis C
LIST OF FIGURES 13 Figure 1: Zepatier for hepatitis C – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Zepatier for hepatitis C
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Zepatier for hepatitis C
17 Figure 4: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES 5 Table 1: Zepatier drug profile
7 Table 2: Pivotal studies supporting approvals of Zepatier
11 Table 3: Zepatier late-phase trial data in hepatitis C
18 Table 4: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017–26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726